WO2023048656A3 - Human monoclonal antibodies against the receptor-binding domain of sars-cov-2 spike protein - Google Patents

Human monoclonal antibodies against the receptor-binding domain of sars-cov-2 spike protein Download PDF

Info

Publication number
WO2023048656A3
WO2023048656A3 PCT/TH2022/000037 TH2022000037W WO2023048656A3 WO 2023048656 A3 WO2023048656 A3 WO 2023048656A3 TH 2022000037 W TH2022000037 W TH 2022000037W WO 2023048656 A3 WO2023048656 A3 WO 2023048656A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
sars
receptor
binding domain
methods
Prior art date
Application number
PCT/TH2022/000037
Other languages
French (fr)
Other versions
WO2023048656A2 (en
Inventor
Trairak PISITKUN
Chatikorn BOONKRAI
Nattachai SRISAWAT
Tossapon WONGTANGPRASERT
Thittaya AUDOMSUN
Tanapati PHAKHAM
Chadaporn ATTAKITBANCHA
Watchadaporn CHAISURIYONG
Original Assignee
Chulalongkorn University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chulalongkorn University filed Critical Chulalongkorn University
Publication of WO2023048656A2 publication Critical patent/WO2023048656A2/en
Publication of WO2023048656A3 publication Critical patent/WO2023048656A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has rapidly spread globally, causing a pandemic. The present disclosure relates to antibodies and antigen-binding fragments that bind specifically to the receptor-binding domain of SARS-CoV-2, compositions thereof, and methods of production. Also provided are methods of use, including methods of SARS-CoV-2 detection, methods for treating or preventing SARS-CoV-2 infections and associated symptoms.
PCT/TH2022/000037 2021-09-24 2022-09-22 Human monoclonal antibodies against the receptor-binding domain of sars-cov-2 spike protein WO2023048656A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163248115P 2021-09-24 2021-09-24
US63/248,115 2021-09-24

Publications (2)

Publication Number Publication Date
WO2023048656A2 WO2023048656A2 (en) 2023-03-30
WO2023048656A3 true WO2023048656A3 (en) 2023-06-08

Family

ID=85721011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TH2022/000037 WO2023048656A2 (en) 2021-09-24 2022-09-22 Human monoclonal antibodies against the receptor-binding domain of sars-cov-2 spike protein

Country Status (1)

Country Link
WO (1) WO2023048656A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200377950A1 (en) * 2008-02-20 2020-12-03 Celera Corporation Genetic polymorphisms associated with stroke, methods of detection and uses thereof
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021180602A1 (en) * 2020-03-12 2021-09-16 Harbour Antibodies Bv Sars-cov-2 (sars2, covid-19) antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200377950A1 (en) * 2008-02-20 2020-12-03 Celera Corporation Genetic polymorphisms associated with stroke, methods of detection and uses thereof
WO2021180602A1 (en) * 2020-03-12 2021-09-16 Harbour Antibodies Bv Sars-cov-2 (sars2, covid-19) antibodies
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE NUCLEOTIDE ANONYMOUS : "Homo sapiens isolate 54042-11 immunoglobulin heavy chain variable region mRNA, partial cds", XP093071770, retrieved from NCBI *

Also Published As

Publication number Publication date
WO2023048656A2 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
WO2021156490A3 (en) Corona virus binders
EP4356924A3 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
JP2009537143A5 (en)
WO2018187706A3 (en) Anti-influenza b virus neuraminidase antibodies and uses thereof
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
CL2010000788A1 (en) Monoclonal antibody or antigen binding fragment thereof that binds to integrin alpha-v-beta-6; pharmaceutical composition that includes it; use to treat or prevent fibrosis, psoriasis, cancer, acute lung damage and alpont syndrome; use to detect integrin alfa-v-beta-6 (div. sol. no. 513-03).
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
NZ627167A (en) Immunomodulating compositions and uses therefor
AR061115A1 (en) ANTI-INTERLEUQUINE ANTIBODIES 18 (IL-18)
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
BR112021023024A2 (en) Antibody against claudin 18a2 and its use
EA200970586A1 (en) HUMAN CYTOMEGAL VIRUS ANTIBODIES (HCMV)
WO2019106578A3 (en) Polyomavirus neutralizing antibodies
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
WO2002043660A3 (en) Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
WO2021195385A8 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
BR112022024149A2 (en) ANTI-SARS-COV-2 SPIKE ANTI-GLYCOPROTEIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
WO2021212021A3 (en) Coronavirus antibodies and methods of use thereof
BR112022024662A2 (en) METHODS FOR TREATMENT OR PREVENTION OF SARS-COV-2 AND COVID-19 INFECTIONS WITH ANTI-SARS-COV-2 SPIKE GLYCOPROTEIN ANTIBODIES
MX2021015156A (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof.
WO2022011110A3 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
WO2023019174A3 (en) Antibodies to sars-cov-2
WO2009054708A3 (en) Antibody therapy for highly pathogenic avian influenza virus
WO2023048656A3 (en) Human monoclonal antibodies against the receptor-binding domain of sars-cov-2 spike protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22873301

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2401001899

Country of ref document: TH

NENP Non-entry into the national phase

Ref country code: DE